Publication:
Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer

dc.contributor.buuauthorDeligönül, Adem
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorAvcı, Nilüfer
dc.contributor.buuauthorUğraş, Nesrin
dc.contributor.buuauthorTüre, Mehmet
dc.contributor.buuauthorÇubukçu, Erdem
dc.contributor.buuauthorHartavi, Mustafa
dc.contributor.buuauthorÖlmez, Ömer Fatih
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorTolunay, Şahsine
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Onkoloji Ana Bilim Dalı
dc.contributor.departmentPatoloji Ana Bilim Dalı
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentTıbbi Genetik Ana Bilim Dalı
dc.contributor.orcid0000-0002-9732-5340
dc.contributor.orcid0000-0002-5771-7649
dc.contributor.researcheridESM-4544-2022
dc.contributor.researcheridAAJ-1027-2021
dc.contributor.researcheridCCT-7946-2022
dc.contributor.researcheridAAH-2716-2021
dc.contributor.researcheridECY-8582-2022
dc.contributor.researcheridETP-1691-2022
dc.contributor.researcheridCUI-5353-2022
dc.contributor.researcheridDJG-4827-2022
dc.contributor.researcheridDAS-3088-2022
dc.contributor.researcheridAAI-1612-2021
dc.contributor.researcheridCYM-0930-2022
dc.contributor.researcheridFLP-9613-2022
dc.contributor.scopusid37088030300
dc.contributor.scopusid6603942124
dc.contributor.scopusid55390409800
dc.contributor.scopusid55386535600
dc.contributor.scopusid6602186133
dc.contributor.scopusid53986153800
dc.contributor.scopusid55370753300
dc.contributor.scopusid26435400000
dc.contributor.scopusid7006207332
dc.contributor.scopusid6602604390
dc.contributor.scopusid55881548500
dc.contributor.scopusid6602587152
dc.date.accessioned2024-01-09T07:42:29Z
dc.date.available2024-01-09T07:42:29Z
dc.date.issued2016
dc.description.abstractPurpose: The clinical value of HER4 - a cell surface receptor that belongs to the human epidermal growth factor receptor family - for predicting survival outcomes in patients with breast cancer remains controversial. Herein, we sought to investigate the prognostic significance of HER4 immunohistochemical expression with respect to progression-free survival (PFS) and overall survival (OS) in Turkish patients with metastatic breast cancer (MBC).Methods: MBC patients (N=45; mean age=50.5 +/- 12.7 years) were consecutively enrolled between 2000 and 2006 in the Department of Oncology at the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections. The predictive value of HER4 expression was investigated by multivariate analysis after allowance for potential confounders.Results: The mean PFS in the study participants was 11.35 months (range:1-50), whereas the median OS was 22.18 months (range:1-76). The mean PFS in patients with a HER4 immunohistochemical score of 0, 1+, 2+, and 3+ was 11.0 +/- 4.8, 11.3 +/- 7.7, 11.7 +/- 8.1, and 10.4 +/- 7.4 months, respectively (p=0.99). The mean OS in patients with a HER4 score of 0, 1+, 2+, and 3+ was 13.3 +/- 6.8, 25.6 +/- 10.8, 22.9 +/- 10.7, and 13.5 +/- 9.9, months, respectively (p=0.44). The results of multivariate Cox regression analysis indicated that the presence of visceral metastases was the only independent prognostic factor for both OS (HR=3.01, 95% CI=1.56-3.99, p <0.01) and PFS (HR=2.91, 95% CI=1.51-3.78, p <0.01).Conclusion: HER4 immunohistochemical expression is not an independent predictor of OS and PFS in Turkish MBC patients.
dc.identifier.citationDeligönül, A. vd. (2016). "Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer". Journal of BUON, 21(3), 564-569.
dc.identifier.endpage569
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue3
dc.identifier.pubmed27569073
dc.identifier.scopus2-s2.0-84994164404
dc.identifier.startpage564
dc.identifier.urihttps://europepmc.org/article/med/27569073
dc.identifier.urihttps://hdl.handle.net/11452/38882
dc.identifier.volume21
dc.identifier.wos000378978900005
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherImprimatur Publications
dc.relation.journalJournal of BUON
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectHER4
dc.subjectImmunochemistry
dc.subjectMetastatic breast cancer
dc.subjectPrognosis
dc.subjectSurvival
dc.subjectProgesterone-receptor
dc.subjectEstrogen-receptor
dc.subjectSystemic therapy
dc.subjectBh3-only protein
dc.subjectCoactivator
dc.subjectERBB4/HER4
dc.subjectCarcinomas
dc.subjectRecurrence
dc.subjectHER4/4ICD
dc.subjectFamily
dc.subject.emtreeAnthracycline
dc.subject.emtreeEpidermal growth factor receptor 2
dc.subject.emtreeEpidermal growth factor receptor 4
dc.subject.emtreeEstrogen receptor
dc.subject.emtreeProgesterone receptor
dc.subject.emtreeTaxane derivative
dc.subject.emtreeEpidermal growth factor receptor 4
dc.subject.emtreeAdult
dc.subject.emtreeArticle
dc.subject.emtreeCancer grading
dc.subject.emtreeCancer localization
dc.subject.emtreeCancer prognosis
dc.subject.emtreeClinical article
dc.subject.emtreeFemale
dc.subject.emtreeFollow up
dc.subject.emtreeHuman
dc.subject.emtreeImmunohistochemistry
dc.subject.emtreeMetastatic breast cancer
dc.subject.emtreeMiddle aged
dc.subject.emtreeOverall survival
dc.subject.emtreeProgression free survival
dc.subject.emtreeProtein expression
dc.subject.emtreeRetrospective study
dc.subject.emtreeTumor growth
dc.subject.emtreeTumor volume
dc.subject.emtreeTurk (people)
dc.subject.emtreeAged
dc.subject.emtreeBreast tumor
dc.subject.emtreeChemistry
dc.subject.emtreeImmunohistochemistry
dc.subject.emtreeMetastasis
dc.subject.emtreeMortality
dc.subject.emtreePathology
dc.subject.emtreePrognosis
dc.subject.emtreeProportional hazards model
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBreast neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry
dc.subject.meshMiddle aged
dc.subject.meshNeoplasm metastasis
dc.subject.meshPrognosis
dc.subject.meshProportional hazards models
dc.subject.meshReceptor, ErbB-4
dc.subject.scopusErbb-3 Receptor; U3-1287; Cancer
dc.subject.wosOncology
dc.titleImmunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer
dc.typeArticle
dc.wos.quartileQ4 (Oncology)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Patoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Tıbbi Genetik Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: